<DOC>
	<DOCNO>NCT01210157</DOCNO>
	<brief_summary>The purpose study determine whether galectin-3 binding protein plasma level predict adverse cardiovascular event patient coronary artery disease and/or heart failure .</brief_summary>
	<brief_title>Galectin-3 Binding Protein Cardiovascular Disease Chronic Heart Failure</brief_title>
	<detailed_description>Chronic heart failure represent important cause disease burden Western country . Heart failure either cause vascular disease ( i.e . cardiomypathy ( CMP ) due coronary artery disease ( `` ischemic/ICMP '' ) ) myocardial condition ( i.e . dilate cardiomyopathy ( DCMP ) result cause like familial disposition , drug toxicity , etc. ) . Gold standard diagnosis CMPs coronary angiography conjunction leave ventricular angiography myocardial biopsy , non-invasive marker include C-reactive protein ( CRP ) ICMP brain natriuretic protein ( BNP ) DCMP . We previously identify G3BP overexpressed foam cell plasma-derived microparticles , potentially important formation atherosclerotic plaque . Galectin-3 binding protein ( G3BP ) secrete protein involve cell adhesion immune activation . The purpose current study test , whether G3BP plasma level ( ) able non-invasively differentiate cause CMP ( b ) suitable mean future risk assessment CMP patient .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>impaired ventricular function neoplastic disease infection hepatitis C HIV</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>